Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Oat-grape probiotic beverage enriched with jambolan extract improves glycemic markers and pancreatic morphology in a rat model of type 2 diabetes.

Created on 02 Nov 2026

Authors

Sara Sayonara da Cruz Nascimento, Alana Natalícia Vasconcelos de Araújo, Januse Míllia Dantas de Araújo, Tainá Rodrigues de Oliveira, Marcos Dos Santos Lima, Adriano Francisco Alves, Jailane de Souza Aquino, Thaís Souza Passos, Francisco Canindé de Sousa Júnior

Published in

Food research international (Ottawa, Ont.). Volume 245. Issue Pt 4. Pages 120890. Dec 01, 2026. Epub Sep 29, 2026.

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease accounting for approximately 90% of all diabetes cases worldwide, highlighting the need for effective prevention and management strategies. This study aimed to evaluate the effects of an oat-grape probiotic beverage enriched with 3% jambolan (Syzygium cumini) extract (PBA3) containing Lactobacillus acidophilus LA14 in Wistar rats with T2DM. Rats were randomized into four groups: healthy control (H), healthy treated with PBA3 (HB), diabetic (D), and diabetic treated with PBA3 (DB). Healthy groups received a standard diet, whereas diabetic groups received a high-sugar diet and streptozotocin (50 mg/kg). PBA3 was administered daily by oral gavage (10 mL/kg) for 4 weeks. Metabolic, inflammatory, and histopathological parameters were evaluated, including glucose homeostasis, insulin sensitivity, glycated hemoglobin (HbA1c), pancreatic histopathology, pancreatic and colonic tumor necrosis factor (TNF) immunoreactivity, and short-chain fatty acids (SCFA) in intestinal contents and feces. Compared with the untreated diabetic group (D), PBA3 improved glucose homeostasis and insulin sensitivity, as demonstrated by significant reductions in fasting glucose, glycated hemoglobin, and HOMA-IR, together with improved insulin tolerance. Treatment also increased SCFA, reuced pancreatic TNF immunoreactivity, and preserved pancreatic islet morphology. These findings provide exploratory preclinical evidence that PBA3 is associated with improved glycemic markers, insulin sensitivity, SCFA, and attenuation of pancreatic inflammatory and structural alterations in this experimental model, supporting further mechanistic and translational investigation of its potential in T2DM management.

PMID:
42967715
Bibliographic data and abstract were imported from PubMed on 02 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement